Our bodies are thought to produce endocannabinoids by the billions every day. “We always thought the ‘runner’s high’ was due to the release of dopamine and endorphins. But now we know the euphoria is also from an endocannabinoid called anandamide,” its name derived from the Sanskrit word for bliss, says Joseph Maroon, M.D., clinical professor and vice chairman of neurosurgery at the University of Pittsburgh Medical Center. We produce these natural chemicals all day, but they fade quickly because enzymes pop up to destroy them. That’s where CBD comes in: By blocking these enzymes, CBD allows the beneficial compounds to linger. This is why Amanda Oliver, 31, a career consultant in Charleston, SC, pops a CBD gummy bear each night before bed. “I used to lie there tossing and turning as my mind raced from work projects to whether I had set the home alarm,” Oliver says. One piece of candy with 15 mg of CBD is enough to shut off her brain and facilitate sleep. She also swears by the CBD oil she takes at the height of her period, which she says quells her debilitating cramps.
According to Delphic analysis by British researchers in 2007, cannabis has a lower risk factor for dependence compared to both nicotine and alcohol. However, everyday use of cannabis may be correlated with psychological withdrawal symptoms, such as irritability or insomnia, and susceptibility to a panic attack may increase as levels of THC metabolites rise. However, cannabis withdrawal symptoms are typically mild and are never life-threatening.
Yet the DEA has stated unequivocally that it considers CBD to be illegal under the Controlled Substances Act. “CBD derived from the cannabis plant is controlled under Schedule I of the CSA because it is a naturally occurring constituent of marijuana,” Joseph Rannazzisi, the deputy assistant administrator of the DEA, told a congressional panel in June. “While there is ongoing research into a potential medical use of CBD, at this time, CBD has no currently accepted medical use in the USA.” Moreover, DEA spokesman Eduardo Chavez told the New Republic that Medical Marijuana, Inc.’s in-house opinion with regards to CBD has no merit. “The bottom line,” Chavez said, “is the oil is part of the marijuana plant, and the marijuana plant is currently a Schedule I controlled substance under federal law.”
From 1982 to 2002 the EU provided the equivalent of about 50 million dollars to develop new flax and hemp harvesting and fiber processing technologies (Karus et al. 2000). Because of the similarities of flax and hemp, the technologies developed for one usually are adaptable to the other. In addition, various European nations and private firms contributed to the development of hemp technologies. Accordingly, Europe is far more advanced in hemp development with respect to all fiber-based applications than other parts of the world. The EU currently dedicates about 30,000 ha to hemp production. France is the leading country in hemp cultivation in the EU, and 95% of the non-seed production is used for “specialty pulp” as described below. Harvesting and processing machinery for fiber hemp is highly advanced in Europe, and some has been imported into Canada. However, there is insufficient fiber processing capacity to handle hemp produced in Canada.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.